Journal of Addiction Medicine最新文献_第5页

Brief Report on Outpatient Treatment of Adolescent Opioid Use Disorder. 青少年阿片类药物使用障碍门诊治疗简要报告》。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-10-23 DOI: 10.1097/ADM.0000000000001391

Sivabalaji Kaliamurthy, Emma Straton, Prianka Kumar, Anna Carleen

{"title":"Brief Report on Outpatient Treatment of Adolescent Opioid Use Disorder.","authors":"Sivabalaji Kaliamurthy, Emma Straton, Prianka Kumar, Anna Carleen","doi":"10.1097/ADM.0000000000001391","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001391","url":null,"abstract":"Objectives: Adolescents are experiencing an increase in substance-related overdose fatalities, with most attributed to fentanyl and an increase in the prevalence of opioid use disorder (OUD). We know little about the characteristics of adolescents who use fentanyl, develop OUD, and seek addiction treatment. Here, we present demographic data and retention data on adolescent patients (≤18 years) who were treated at a pediatric addiction clinic.Methods: We included all patients who presented to an intake appointment at the pediatric addiction clinic between January 3, 2023, and October 17, 2023, and were diagnosed with OUD. We collected data on demographics, decision to start medicine for OUD (MOUD), choice of MOUD, and retention in treatment based on clinic visits at 1 month and 3 months postintake.Results: Patients are consisted of 24 adolescents (Mage at intake = 16.8 ± 1.0 years, 67% Hispanic/Latinx, 75% public insurance) who met the criteria for moderate to severe OUD with known fentanyl use. All were offered MOUD, and 21 patients agreed to MOUD treatment; 16 adolescents selected buprenorphine/naloxone, and 5 selected naltrexone. At 3 months postintake, 14 patients (58%) were retained in treatment.Conclusions: Adolescent and family acceptance of MOUD treatment was high, and most patients were retained in treatment at 3 months postintake. More studies are needed to understand how to retain and support adolescent patients in outpatient treatment for OUD given the emergence of fentanyl.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142500743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Association Between Variables and Transitions Among No Opioid Use, Opioid Use, and Subsequent Dropout Among Participants on Methadone Treatment: A Retrospective Study Utilizing a Multistate Model. 美沙酮治疗参与者中未使用阿片类药物、使用阿片类药物和随后退出治疗之间的变量和转变之间的关系：利用多州模型进行的回顾性研究。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-10-18 DOI: 10.1097/ADM.0000000000001370

Boyu Li, Chijie Wang, Xijia Tang, Zouxiang Chen, Zhiyao Li, Wensu Zhou, Wen Chen, Li Ling

{"title":"Association Between Variables and Transitions Among No Opioid Use, Opioid Use, and Subsequent Dropout Among Participants on Methadone Treatment: A Retrospective Study Utilizing a Multistate Model.","authors":"Boyu Li, Chijie Wang, Xijia Tang, Zouxiang Chen, Zhiyao Li, Wensu Zhou, Wen Chen, Li Ling","doi":"10.1097/ADM.0000000000001370","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001370","url":null,"abstract":"Background: Although previous studies have reported the variables that influence opioid use or dropout among participants receiving methadone treatment, limited attention has been given to the variables related to transitions among no opioid use, opioid use, and dropout.Methods: This retrospective study utilized data collected from June 2010 to June 2022 at 11 methadone treatment clinics in Guangdong Province, China. Two transient states (no opioid use and opioid use) and 1 absorbing state (dropout) were defined based on monthly urine morphine test results and daily methadone intake records. We used a multistate model to explore the variables associated with transitions among no opioid use, opioid use, and dropout among participants.Results: Among 3136 participants, with an average treatment duration of 497 days, 1646 (52.49%) underwent at least 1 period of opioid use, resulting in 3283 transitions from no opioid use to opioid use. The transitions between no opioid use and opioid use were significantly associated with variables such as age, gender, employment status, marital status, living situation, travel time to the clinic, human immunodeficiency virus and hepatitis C virus infection statuses, average methadone dosage, and attendance rates. The variables influencing participants' dropout varied depending on their opioid use behaviors. Additionally, the probability of a specified opioid use state remaining unchanged or transitioning to a different state at a defined time point would change over time.Conclusions: The opioid use behaviors of participants are dynamic. Methadone providers should offer targeted interventions based on participants' opioid use behaviors to effectively decrease rates of opioid use and improve retention.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

30-Month Impact of Medications for Opioid Use Disorder on Acute Care Utilization in Rural Communities. 阿片类药物使用障碍 30 个月对农村社区急症护理使用率的影响》（Medications for Opioid Use Disorder on Acute Care Utilization in Rural Communities）。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-10-16 DOI: 10.1097/ADM.0000000000001385

Daniel Maeng, Holly A Russell, Kenneth R Conner, Jade Malcho, Wendi Cross, Hochang B Lee

{"title":"30-Month Impact of Medications for Opioid Use Disorder on Acute Care Utilization in Rural Communities.","authors":"Daniel Maeng, Holly A Russell, Kenneth R Conner, Jade Malcho, Wendi Cross, Hochang B Lee","doi":"10.1097/ADM.0000000000001385","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001385","url":null,"abstract":"Purpose: To assess both the short- and longer-term impact of offering medications for opioid use disorder (MOUD, ie, methadone, buprenorphine, or naltrexone) on rates of all-cause emergency department (ED) visits and acute inpatient admissions (IP) over a 30-month period among Medicaid enrollees with opioid use disorder (OUD) residing in rural communities.Methods: A quasi-experimental retrospective analysis of longitudinal Medicaid claims data among continuously enrolled adult patients with OUD residing in 71 predominantly rural counties in the United States between 2018 and 2020. A cohort of patients receiving MOUD treatment was compared against a contemporaneous propensity score-matched comparison group consisting of those who received no MOUD during the period.Findings: The sample included 5370 patients with OUD in each group. At the index period (ie, the month in which any MOUD was used for the first time), buprenorphine was the most commonly used MOUD (82% of the MOUD treatment group). By the eighth month since the index period, MOUD use dropped below 60% among the MOUD treatment group. Over the 30-month post-MOUD period, MOUD treatment was associated with 24% (112 vs 148 per 1000 per month) and 52% (21 vs 44) lower rates of ED visit and IP admission rates, respectively (P < 0.001), relative to the comparison group. Moreover, the reductions persisted well after the 18th month period.Conclusions: Receipt of MOUD was associated with both immediate- and long-term lower rates in acute care utilization rates among adult Medicaid beneficiaries with OUD residing in rural communities despite significant treatment discontinuation.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142465898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Personal Experiences With Xylazine and Behavior Change: A Qualitative Content Analysis of Reddit Posts. 使用赛拉嗪和行为改变的个人经历：对 Reddit 帖子的定性内容分析。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-09-27 DOI: 10.1097/ADM.0000000000001383

Omeid Heidari, Olivia K Sugarman, Abigail K Winiker, Sabrina Gattine, Vivian Flanagan, Roham Razaghi, Brendan K Saloner

{"title":"Personal Experiences With Xylazine and Behavior Change: A Qualitative Content Analysis of Reddit Posts.","authors":"Omeid Heidari, Olivia K Sugarman, Abigail K Winiker, Sabrina Gattine, Vivian Flanagan, Roham Razaghi, Brendan K Saloner","doi":"10.1097/ADM.0000000000001383","DOIUrl":"10.1097/ADM.0000000000001383","url":null,"abstract":"Objectives: Xylazine is a rapidly spreading adulterant in the United States' drug supply and is increasingly associated with overdoses and severe wounds, but there is a dearth of information about the clinical presentation or means of treatment for human xylazine exposure. The objective of this study was to explore personal attitudes about xylazine in the drug supply and experiences with xylazine-related use among people who reported using drugs and contributed content to social media site Reddit.Methods: To conduct a retrospective qualitative content analysis, the study team extracted all posts and comments from Reddit, which mentioned the terms \"xylazine\" or \"tranq.\" Content was extracted from 10 Reddit forums, or subreddits, specific to drug use, and included content created on or before the extraction date of January 2023. In total, 3284 posts were identified and 1803 were qualitatively coded using an inductive approach until meaning saturation was reached.Results: Three themes emerged across comments and posts: (1) personal experiences with xylazine, including a negative impact on overdose, withdrawal, and wounds; (2) behavior changes in response to xylazine in the drug supply, including devising and sharing new harm reduction and detection tips, and reducing or abstaining from drug use altogether; (3) a perceived lack of treatment options for xylazine withdrawal and information sharing to help others self-treat withdrawal symptoms, most often with clonidine.Conclusions: This study of people who reported using drugs with xylazine provides new insights into how xylazine is perceived, possible treatment modalities, and potential clinical research approaches.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

5-Day Injectable Extended-release Buprenorphine Initiation in Non-opioid-tolerant Individuals in a Carceral Setting: A Case Series. 在囚禁环境中对阿片类药物无耐受性的人开始使用 5 天注射型缓释丁丙诺啡：病例系列。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-09-27 DOI: 10.1097/ADM.0000000000001387

Matt Perdue, Reza Hosseini Ghomi, Paul Rees, Eric Arzubi

{"title":"5-Day Injectable Extended-release Buprenorphine Initiation in Non-opioid-tolerant Individuals in a Carceral Setting: A Case Series.","authors":"Matt Perdue, Reza Hosseini Ghomi, Paul Rees, Eric Arzubi","doi":"10.1097/ADM.0000000000001387","DOIUrl":"https://doi.org/10.1097/ADM.0000000000001387","url":null,"abstract":"Background: Injectable extended-release buprenorphine (XR-Bup) addresses several barriers to the implementation of treatment with medications for opioid use disorder (MOUD) in carceral settings due to lower risk of diversion and reduced operational procedures. However, there is no standardized approach or guideline for initiating sublingual buprenorphine (SL-Bup) and transitioning to XR-Bup in persons with opioid use disorder (OUD) who are not actively using opioids, a clinical scenario commonly encountered in carceral settings.Methods: We conducted a retrospective case series of non-opioid-tolerant men with OUD at a Montana Department of Corrections facility who initiated XR-Bup using a 5-day induction protocol between May 1, 2023, and November 1, 2023. Primary outcome was receipt of the initial XR-Bup injection. Secondary outcomes were toleration of SL-Bup induction protocol and active continuation of XR-Bup at time of discharge.Results: Sixteen individuals initiated the SL-Bup induction protocol, and all were successfully transitioned to XR-Bup with no severe adverse effects. There were no required dose changes or severe adverse effects from SL-Bup induction. Two (12%) elected to discontinue XR-Bup due to commonly reported adverse effects. Fourteen (88%) remained on XR-Bup at discharge.Conclusions: Five-day induction of SL-Bup and transition to XR-Bup may be considered for non-opioid-tolerant individuals with OUD in carceral settings.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142346997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Maternal Perception of Infant Sleep and Bonding in Opioid Use Disorder. 阿片类药物使用失调症中母亲对婴儿睡眠和亲情的感知。

IF 5.5 3区医学

Journal of Addiction Medicine Pub Date : 2024-09-11 DOI: 10.1097/adm.0000000000001381

Joyce H Xu,Stephanie L Merhar,Emily A Defranco,Jennifer M McAllister,Mishka Terplan,Nichole L Nidey

{"title":"Maternal Perception of Infant Sleep and Bonding in Opioid Use Disorder.","authors":"Joyce H Xu,Stephanie L Merhar,Emily A Defranco,Jennifer M McAllister,Mishka Terplan,Nichole L Nidey","doi":"10.1097/adm.0000000000001381","DOIUrl":"https://doi.org/10.1097/adm.0000000000001381","url":null,"abstract":"OBJECTIVEInfant sleep problems are common in early infancy and can negatively influence maternal-infant bonding. As opioid-exposed neonates are at increased risk of sleep difficulties, we examined the association between maternal perception of infant sleep difficulties and maternal-infant bonding among dyads affected by maternal opioid use disorder (OUD), from birth through 6 months.METHODSWe enrolled 100 birthing people (participants) between 6 months and 2 years postpartum who had received medications for OUD during their pregnancy. Participants answered questions regarding maternal and infant characteristics, as well as the Postpartum Bonding Questionnaire (PBQ), on which higher scores indicate decreased maternal-infant bonding. Unadjusted and adjusted linear regression models were used to examine the association between infant sleep and bonding.RESULTSOf 100 study participants, 91 completed the PBQ. Of these, 55% reported difficulties with their infant's sleep during the first 6 months postpartum. Although bonding scores were overall strong, those who reported infant sleep difficulties scored on average 10.40 points higher on the PBQ (β = 10.40; 95% confidence interval, 5.94-14.85) than participants who did not report sleep difficulties, indicating the negative association between infant sleep problems and bonding. This effect remained after adjusting for relevant maternal-infant characteristics (β = 6.86; 95% confidence interval, 2.49-11.24).CONCLUSIONSIn this study among postpartum individuals with OUD, maternal perception of infant sleep problems was associated with reduced maternal-infant bonding. This relationship between infant sleep and bonding offers a target for supporting dyads affected by OUD.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":"74 1","pages":""},"PeriodicalIF":5.5,"publicationDate":"2024-09-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142192433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to "Two Clinical Insights on Methamphetamine Withdrawal at a Safety-Net Hospital". 回应 "一家安全网医院对甲基苯丙胺戒断的两点临床见解"。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-09-04 DOI: 10.1097/ADM.0000000000001364

Timothy E Wilens, Ronan L H Wilson, Lia Beltrame, Adam Taylor, James O'Connell

引用次数: 0

Medications for Alcohol Use Disorder among Birthing People with an Alcohol-related Diagnosis. 在被诊断患有酒精相关疾病的分娩人群中使用药物治疗酒精使用障碍。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-09-04 DOI: 10.1097/ADM.0000000000001372

Sarah Cm Roberts, Guodong Liu, Mishka Terplan

{"title":"Medications for Alcohol Use Disorder among Birthing People with an Alcohol-related Diagnosis.","authors":"Sarah Cm Roberts, Guodong Liu, Mishka Terplan","doi":"10.1097/ADM.0000000000001372","DOIUrl":"10.1097/ADM.0000000000001372","url":null,"abstract":"Objectives: Although safety and effectiveness of medications for alcohol use disorder (AUD) are well established for adults, literature on these medications in pregnancy is limited. Given known adverse effects of untreated AUD during pregnancy, clinicians and researchers have recently begun to call for reconsidering use of medications for AUD in pregnancy. Thus, we sought to estimate the proportion of birthing people with an alcohol-related diagnosis who received a prescription for medication related to AUD treatment.Methods: Data were from Meritive MarketScan, a national private insurance claims database. The study cohort included birthing people aged 25-50 who gave birth to a singleton in the United States between 2006 and 2019 and were matched with an infant. Variables included an alcohol-related diagnosis within a year of birth and receiving a prescription for a medication related to AUD treatment. We calculated proportions with alcohol-related diagnoses who received any AUD medication and each medication type.Results: Of 1,432,979 birthing person-infant dyads, 2517 (0.18%) had an alcohol-related diagnosis. Of those with an alcohol-related diagnosis, 8.70% (n = 219) received any medication. The most common was gabapentin (4.69%, n = 118), with benzodiazepines for withdrawal as the second most common (2.19%, n = 55). Approximately 2% received naltrexone (1.91%, n = 48) and/or disulfiram (1.39%, n = 35); 0.56% (n = 14) received acamprosate. No one with an alcohol-related diagnosis received phenobarbital. Almost all medications were received postpartum.Conclusions: Very few pregnant/postpartum people with alcohol-related diagnoses are prescribed medications related to AUD treatment. Research is needed to examine whether benefits of these medications during pregnancy outweigh harms.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142125774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Two Clinical Insights on Methamphetamine Withdrawal at a Safety-Net Hospital. 一家安全网医院对甲基苯丙胺戒断的两种临床见解。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-09-04 DOI: 10.1097/ADM.0000000000001365

Dale Terasaki, Ryan Loh, Scott Simpson

引用次数: 0

Naloxone Stigma Among People Who Use Drugs: Characteristics and Associations With Stigma Toward Medication for Opioid Use Disorder. 吸毒者对纳洛酮的成见：吸毒者对纳洛酮的成见：对阿片类药物使用障碍的成见的特征和关联。

IF 4.2 3区医学

Journal of Addiction Medicine Pub Date : 2024-09-04 DOI: 10.1097/ADM.0000000000001377

Devin E Banks, Xiao Li, Brandon Park, Rachel P Winograd, Patricia Cavazos-Rehg

{"title":"Naloxone Stigma Among People Who Use Drugs: Characteristics and Associations With Stigma Toward Medication for Opioid Use Disorder.","authors":"Devin E Banks, Xiao Li, Brandon Park, Rachel P Winograd, Patricia Cavazos-Rehg","doi":"10.1097/ADM.0000000000001377","DOIUrl":"10.1097/ADM.0000000000001377","url":null,"abstract":"Objectives: Widespread naloxone distribution is key to mitigating opioid-related morbidity, but stigma remains a barrier. Naloxone stigma among providers, emergency responders, and the public is well-documented and associated with treatment and policy preferences, but little is known about naloxone stigma among people who use drugs (PWUD), who may be overdose first responders. This study examines naloxone stigma, its correlates, and its association with stigma toward medication for opioid use disorder (MOUD) among PWUD.Methods: We recruited 293 individuals with a history of substance misuse from facilities that provide substance use and/or health care services (retained n = 195, 54% women, 75% White). Participants completed self-report measures, including the 5-item Naloxone-Related Risk Compensation Beliefs scale.Results: One in 5 respondents agreed with beliefs that access to naloxone leads to more opioid use and less treatment seeking and is \"enabling.\" Those with nonopioid drug misuse, without prior overdose, and with fewer recovery attempts endorsed more naloxone stigma. Opioid misuse, prior overdose, and MOUD utilization were also inversely associated with MOUD stigma. There were no demographic differences in either stigma type. Naloxone stigma was positively associated with MOUD stigma in adjusted models.Conclusions: This is the first study to quantitatively examine naloxone stigma among PWUD. Findings emphasize the potential role of overdose education and naloxone distribution among those earlier in the substance use disorder course and who use nonopioid drugs. They support integrating MOUD stigma interventions into current overdose education and naloxone distribution targeted at PWUD to increase the acceptance and uptake of both medications.","PeriodicalId":14744,"journal":{"name":"Journal of Addiction Medicine","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142132726","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0